Design Considerations for AIDS Trials
New England Journal of MedicinePublished 8 November 1990
David P. Byar, David Schoenfeld, S B Green, D. A. Amato, Ray S. Davis, Victor De Gruttola
Citations141
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
This poster aims to demonstrate the power of data-driven, evidence-based approaches to improve the quality of life for patients with acquired immunodeficiency.
Abstract
Patients with AIDS, activist groups such as ACT UP (AIDS Coalition to\nUnleash Power), and some AIDS researchers argue that the traditional\napproaches to the randomized clinical trial are unsuitable for AIDS research. \nThe 22 statistician-authors of this Sounding Board article meet periodically\nto consider issues related to their work in AIDS clinical trials. This\narticle evolved in response to an ACT UP document,
Keywords
Immunology and MicrobiologyMedicine
New England Journal of MedicineThe Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
2,982 Citations1987Margaret A. Fischl, Douglas D. Richman +12 more
It is demonstrated that AZT administration can decrease mortality and the frequency of opportunistic infections in a selected group of subjects with AIDS or AIDS-related complex, at least over the 8 to 24 weeks of observation in this study.
New England Journal of MedicineZidovudine in Asymptomatic Human Immunodeficiency Virus Infection
1,293 Citations1990Paul A. Volberding, Stephen W. Lagakos +18 more
Zidovudine is safe and effective in persons with asymptomatic HIV infection and fewer than 500 CD4+ cells per cubic millimeter and additional study will be required to determine whether such treatment will ultimately improve survival for persons infected with HIV.
New England Journal of MedicineQuantitation of Human Immunodeficiency Virus Type 1 in the Blood of Infected Persons
1,078 Citations1989David D. Ho, Tarsem Moudgil +1 more
New England Journal of MedicinePlasma Viremia in Human Immunodeficiency Virus Infection
565 Citations1989Robert W. Coombs, Ann C. Collier +5 more
It is concluded that plasma viremia is a more sensitive virologic marker of the clinical stage of HIV infection and viral replication than the presence of p24 antigen or antibody in plasma.
New England Journal of MedicineRandomized Clinical Trials
534 Citations1976David P. Byar, Richard Simon +6 more
Ethical considerations suggest that randomized trials are more suitable than uncontrolled experimentation in protecting the interests of patients and Randomized clinical trials remain the most reliable method for evaluating the efficacy of therapies.
ScienceIn Vivo Activity Against HIV and Favorable Toxicity Profile of 2′,3′-Dideoxyinosine
425 Citations1989Robert Yarchoan, Hiroaki Mitsuya +8 more
Results suggest that serious short-term toxicity at therapeutic doses is not an inherent feature in the profile of agents with clinical anti-HIV activity and further controlled studies to define the safety and efficacy of this agent may be worth considering.
BiometrikaTwo-stage selection and testing designs for comparative clinical trials
204 Citations1988Peter F. Thall, Richard Simon +1 more
A new approach to the problem of identifying the best of K experimental treatments and determining whether it is superior to a control is proposed, dealing with the binomial setting where patient response may be characterized as either success or failure.
BiometricsA Two-Stage Design for Choosing among Several Experimental Treatments and a Control in Clinical Trials
182 Citations1989Peter F. Thall, Richard Simon +1 more
A two-stage design is proposed in which patients are first randomized among the experimental treatments, and the single treatment having the highest observed success rate is identified, and if this highest rate falls below a fixed cutoff then the trial is terminated.
The Journal of Infectious DiseasesThe Natural History of Human Immunodeficiency Virus Infection
168 Citations1988A R Lifson, G W Rutherford +1 more
Exposure to a variety of infectious or environmental agents (such as through sexually transmitted diseases or injection of iv drugs) may accelerate progression to disease in HIV-infected persons.
Statistics in MedicineAssessing apparent treatment—covariate interactions in randomized clinical trials
93 Citations1985David P. Byar
The nature and interpretation of various kinds of interactions are reviewed, the use of overall tests for interaction to subset analysis is compared, and some examples of apparent treatment-covariate interactions that have arisen in actual randomized clinical trials are presented.
BMJPredicting who will progress to AIDS.
69 Citations1988A. R. Moss
The epidemiological data suggest that AIDS should be thought of as the late stage of a long term mostly asymptomatic "HIV disease." Doctors must decide whether they want to use antiviral treatment in the long asymPTomatic period, and thus interest in trying to predict which patients infected with HIV will develop AIDS is increasing.
The American Journal of MedicineProgression to AIDS in patients with lymphadenopathy or AIDS-related complex: reappraisal of risk and predictive factors
43 Citations1989Henry W. Murray, James Godbold +2 more
These updated results demonstrate the remarkably poor prognosis of patients with generalized lymphadenopathy or AIDS-related complex irrespective of initial clinical, immunologic, and serologic findings, and suggest that essentially all such persons may be candidates for antiviral therapy.
Clinical Infectious DiseasesTreatment of Cytomegalovirus Retinitis in Patients with AIDS
40 Citations1988John Mills, Mark Z. Jacobson +3 more
Therapy with ganciclovir (9[(1,3-dihydroxy-2-propoxy)methyl]guanine) has been shown to halt progression of retinitis and may result in limited healing in some cases; viremia and shedding of virus from other sites (such as the urine) are halted or reduced.
Clinical Infectious DiseasesClinical Aspects of Cytomegalovirus Retinitis
38 Citations1988Alan G. Palestine
The response to therapy with 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine (DHPG, ganciclovir) has represented a significant improvement in the management of this disease.
Controlled Clinical TrialsA design for phase II testing of anticancer agents within a phase III clinical trial
31 Citations1988Daniel J. Schaid, James N. Ingle +2 more
A design for testing new anticancer agents is proposed such that the initial testing of new agents is included within the framework of a comparative clinical trial (phase III).
Controlled Clinical TrialsIssues in the design of drug trials for AIDS
18 Citations1990Sylvan B. Green, Susan S. Ellenberg +7 more
A group of biostatisticians has discussed and written a report on a number of issues, primarily related to principles of study design, with the goal of stimulating thought on new study designs and the timely implementation of well-designed trials to identify effective treatment strategies for HIV-infected populations.
Controlled Clinical TrialsMethodological issues in AIDS clinical trials
4 Citations1992Dianne M. Finkelstein